Drug
Combination product: Trastuzumab + Pertuzumab
Combination product: Trastuzumab + Pertuzumab is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Not yet recruiting2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
not_yet_recruiting267%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582
not_yet_recruitingphase_2
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
NCT07527806
not_yet_recruiting
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
NCT07470203
Clinical Trials (3)
Showing 3 of 3 trials
NCT05132582Phase 3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT07527806Phase 2
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
NCT07470203
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3